NCT04548791 — Factor VII Deficiency trial site landscape

Public-registry site landscape for NCT04548791, “Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders”, a Factor VII Deficiency study sponsored by Catalyst Biosciences. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT04548791 (registry record)
Study title	Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
Official title	Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog Alfa (Activated) in Treatment of Episodic Bleeding in Subjects With Inherited Bleeding Disorders
Sponsor	Catalyst Biosciences
Condition(s)	Factor VII Deficiency; Glanzmann Thrombasthenia; Hemophilia A With Inhibitor
Phase	PHASE1 / PHASE2
Listed sites	20
Site countries	United States, India, Italy, Russia, Ukraine

Patient-friendly overview of this study: eichor.com/study/NCT04548791.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT04548791 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →